{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:13:25Z","timestamp":1767982405548,"version":"3.49.0"},"reference-count":26,"publisher":"EDITORA SCIENTIFIC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Bras. Psiquiatr."],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p>OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg\/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS: Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups. CONCLUSION: Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.<\/jats:p>","DOI":"10.1590\/s1516-44462003000300007","type":"journal-article","created":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T16:17:48Z","timestamp":1114532268000},"page":"156-159","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of acamprosate in the treatment of alcohol-dependent outpatients"],"prefix":"10.47626","volume":"25","author":[{"given":"Danilo Antonio","family":"Baltieri","sequence":"first","affiliation":[{"name":"University of S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Guerra de","family":"Andrade","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27448","reference":[{"key":"ref1","series-title":"Drogas: atualiza\u00e7\u00e3o em preven\u00e7\u00e3o e tratamento","first-page":"107","volume-title":"Tratamento farmacol\u00f3gico das drogadepend\u00eancias","author":"Scivoletto S","year":"1993"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0193-953X(18)30197-7","article-title":"Overview of pharmacological treatment approaches for alcohol and other drug addiction","volume":"16","author":"Gorelick D","year":"1993","journal-title":"Psychiatr Clin North Am","ISSN":"https:\/\/id.crossref.org\/issn\/0193-953X","issn-type":"print"},{"key":"ref3","series-title":"Essentials of clinical psychopharmacology","first-page":"519","volume-title":"Treatment of substance-related disorders","author":"Cornish JW","year":"2001","edition":"1"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1360-0443.1997.tb02966.x","article-title":"New drug treatments for alcohol problems: a critical appraisal","volume":"92","author":"Moncrieff J","year":"1997","journal-title":"Addiction","ISSN":"https:\/\/id.crossref.org\/issn\/0965-2140","issn-type":"print"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0376-8716(95)01169-Y","article-title":"The treatment of alcoholism in France","volume":"39","author":"Batel P","year":"1995","journal-title":"Drug Alcohol Depend","ISSN":"https:\/\/id.crossref.org\/issn\/0376-8716","issn-type":"print"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1530-0277.1998.tb03871.x","article-title":"Mechanism of action of acamprosate: Part I. Characterization of spermide-sensitive acamprosate binding site in rat brain","volume":"22","author":"Naassila M","year":"1998","journal-title":"Alc Clin Exp Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0925-4927(98)00016-X","article-title":"Central effects of acamprosate: Pat 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats","volume":"82(2)","author":"Dahchour A","year":"1998","journal-title":"Psychiatry Res","ISSN":"https:\/\/id.crossref.org\/issn\/0165-1781","issn-type":"print"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(93)90682-8","article-title":"Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors","volume":"231","author":"Zeise ML","year":"1993","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(96)00696-6","article-title":"The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal","volume":"317","author":"Putzke J","year":"1996","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"key":"ref10","first-page":"175","article-title":"L'Acamprosate","volume":"16","author":"Nalpas B","year":"1990","journal-title":"De la pharmacologie \u00e0 la clinique. Encephale"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","article-title":"Acamprosate in alcohol dependence: how does it work?","volume":"90","author":"Littleton J.","year":"1995","journal-title":"Addiction","ISSN":"https:\/\/id.crossref.org\/issn\/0965-2140","issn-type":"print"},{"issue":"1","key":"ref12","first-page":"39","article-title":"Acamprosate and alcohol: I","volume":"305","author":"Spanagel R","year":"1996","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000026691","article-title":"Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation","volume":"42","author":"Wohlfarth K","year":"2000","journal-title":"Neuropsychobiology","ISSN":"https:\/\/id.crossref.org\/issn\/0302-282X","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0091-3057(92)90210-7","article-title":"Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats","volume":"41(4)","author":"Daoust M","year":"1992","journal-title":"Pharmacol Biochem Behav","ISSN":"https:\/\/id.crossref.org\/issn\/0091-3057","issn-type":"print"},{"key":"ref15","series-title":"International classification of diseases","year":"1992","edition":"10"},{"key":"ref16","series-title":"Escalas de avalia\u00e7\u00e3o cl\u00ednica em psiquiatria e psicofarmacologia","first-page":"235","volume-title":"Escalas de avalia\u00e7\u00e3o de efeitos colaterais de antipsic\u00f3ticos","author":"Louz\u00e3 Neto MR","year":"2000"},{"key":"ref17","series-title":"Practical statistics for medical research","first-page":"365","volume-title":"Analysis of Survival Times","author":"Altman DG","year":"1991"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","article-title":"Relapsed prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence","volume":"53","author":"Sass H","year":"1996","journal-title":"Arch Gen Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"9013","key":"ref19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(96)91682-7","article-title":"Comparison of acamprosate and placebo in long-term treatment of alcohol dependence","volume":"347","author":"Whitworth AB","year":"1996","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1360-0443.1997.tb02873.x","article-title":"Acamprosate treatment in a long-term community-based alcohol rehabilitation programme","volume":"92","author":"Poldrugo F","year":"1997","journal-title":"Addiction","ISSN":"https:\/\/id.crossref.org\/issn\/0965-2140","issn-type":"print"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","article-title":"Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain","volume":"36","author":"Gual A","year":"2001","journal-title":"Alcohol Alcohol","ISSN":"https:\/\/id.crossref.org\/issn\/0703-2951","issn-type":"print"},{"issue":"2","key":"ref22","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"PAiLLE FM","year":"1995","journal-title":"Alcohol Alcohol","ISSN":"https:\/\/id.crossref.org\/issn\/0703-2951","issn-type":"print"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kington multicentre acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapsed after withdrawal from alcohol","volume":"35","author":"Chick J","year":"2000","journal-title":"Alcohol Alcohol","ISSN":"https:\/\/id.crossref.org\/issn\/0703-2951","issn-type":"print"},{"issue":"2","key":"ref24","first-page":"65","article-title":"Does acamprosate diminish the appetite for alcohol in weaned alcoholics?","volume":"51","author":"Roussaux JP","year":"1996","journal-title":"J Pharm Belg","ISSN":"https:\/\/id.crossref.org\/issn\/0047-2166","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients","volume":"171","author":"Pelc I","year":"1997","journal-title":"Brit J Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(85)91615-0","article-title":"Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapsed in weaned alcoholics","volume":"4","author":"Lhuintre JP","year":"1985","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"}],"container-title":["Revista Brasileira de Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rbp\/v25n3\/a07v25n3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T16:11:00Z","timestamp":1654531860000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-44462003000300007&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["S1516-44462003000300007"],"URL":"https:\/\/doi.org\/10.1590\/s1516-44462003000300007","relation":{},"ISSN":["1516-4446"],"issn-type":[{"value":"1516-4446","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}